Cytosine Arabinoside and Mitoxantrone Followed by Second Allogeneic Transplant for the Treatment of Children With Refractory Juvenile Myelomonocytic Leukemia

Hematopoietic stem cell transplantation (HSCT) remains the only curative option for most patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and relapse rates after transplant range from 26% to 58%. We report the successful use of second HSCT after preparation with mit...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Sachit A., Coulter, Don W., Grovas, Alfred C., Gordon, Bruce G., Harper, James L., Warkentin, Phyllis I., Wisecarver, James L., Sanger, Warren G., Coccia, Peter F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048652/
https://www.ncbi.nlm.nih.gov/pubmed/24322499
http://dx.doi.org/10.1097/MPH.0000000000000077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4048652/
https://www.ncbi.nlm.nih.gov/pubmed/24322499
http://dx.doi.org/10.1097/MPH.0000000000000077

Ejemplares similares